Survival of Patients With Peripheral T-Cell Lymphoma After First Relapse or Progression: Spectrum of Disease and Rare Long-Term Survivors

Mak, Vivien; Hamm, Jeremey; Chhanabhai, Mukesh; Shenkier, Tamara; Klasa, Richard; Sehn, Laurie H.; Villa, Diego; Gascoyne, Randy D.; Connors, Joseph M.; Savage, Kerry J.

doi:10.1200/jco.2012.44.7524

Cited by 348 publications

(260 citation statements)

References 15 publications

Supporting

Mentioning

236

Contrasting

Unclassified

Order By: Relevance

“…Yet recent data from Mak et al did not indicate any differences in outcome between patients with various systemic PTCL subtypes at relapse, even systemic ALCL, who cannot undergo hematopoietic stem cell transplantation. 9 Altogether, these data further suggest that BV especially improves the outcome of ALCL patients at relapse compared to non-ALCL PTCL.…”

mentioning

confidence: 55%

See 1 more Smart Citation

Brentuximab vedotin in refractory or relapsed peripheral T-cell lymphomas: the French named patient program experience in 56 patients

et al. 2015

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 55%

“…Mathilde Lamarque, 1,2,3 Céline Bossard, 4 Adrien Contejean, 5,6 Pauline Brice, 6 Marie Parrens, 7 Steven Le Gouill, 8,9 Josette Brière, 10 Reda Bouabdallah, 11 …”

Section: 1112unclassified

Brentuximab vedotin in refractory or relapsed peripheral T-cell lymphomas: the French named patient program experience in 56 patients

et al. 2015

View full text Add to dashboard Cite

show abstract

“…4 In addition, similar to other peripheral T-cell lymphoma, relapsed ATLL is often refractory to salvage chemotherapies. 15 Taking these poor clinical outcomes into consideration, it is likely that early application of allo-HSCT for patients with ATLL will be able to improve the clinical outcome as in high-risk AML.…”

Section: Discussionmentioning

confidence: 99%

Early application of related SCT might improve clinical outcome in adult T-cell leukemia/lymphoma

Fuji¹,

Fujiwara

Nakano

et al. 2015

Bone Marrow Transplant

View full text Add to dashboard Cite

“…Current treatment strategies are inadequate and survival at relapse is extremely poor, especially in the transplant ineligible group. 74 Although a plethora of new drugs have been trialed in the relapse setting, progressive free survival and OS remain disappointing. The use of intelligent combinations combined with a biomarker-driven approach is likely to be a fruitful avenue of further research.…”

Section: Discussionmentioning

confidence: 99%

New Therapies in T-cell Lymphoma

2014

Lymphoma and Chronic Lymphocytic Leukemias

View full text Add to dashboard Cite

T-cell lymphomas represent 10-12% of all patients with non-Hodgkin lymphoma (NHL) in the Western world. When cutaneous T-cell lymphoma (CTCL) is excluded, peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), anaplastic large-cell lymphoma (ALCL), and angioimmunoblastic T-cell lymphoma (AITL) represent the overwhelming majority of patients in this population. These diseases remain a great challenge to treat. They are characterized by an aggressive presentation, extranodal disease, paraneoplastic phenomena, and resistance to standard chemotherapeutics. With the rapid development of new molecular gene profiling techniques, it is highly likely that these diseases will be subclassified by molecular abnormalities in the future. An evolving understanding of the tumor molecular pathogenesis will undoubtedly lead to further novel targeted therapies. Immunoconjugates, such as brentuximab vedotin (BV), have provided outstanding responses in relapsed, refractory CD30-positive ALCL. Histone deacetylase (HDAC) inhibitors have shown activity in PTCL and are potentially synergistic with proteasome inhibitors. Denileukin diftitox is an interesting recombinant DNA fusion protein linking fragments of the diphtheria toxin to interleukin-2 (IL-2) that is tested in clinical trials. Crizotinib, a highly specific anaplastic lymphoma kinase (ALK) inhibitor, has shown great promise in small number of patients with ALK-positive ALCL; the future of patients with this disorder looks very promising. Biomarker-driven chemotherapeutics is becoming a critical part of the state-of-the-art treatment in early-and late-phase clinical trials. It is crucial that future trials include sensible biomarker-based designs when future treatments are used in these challenging disorders.KEY WORDS: T cell lymphoma, angioimmunoplastic lymphoma, anaplastic large cell lymphoma, brentuximab, crizotinib disclose no potential conflicts of interest.COPYRIGHT: © the authors, publisher and licensee Libertas academica Limited. this is an open-access article distributed under the terms of the Creative Commons CC-By-nC 3.0 License. CORRESPONDENCE: graham.collins@ouh.nhs.uk this paper was subject to independent, expert peer review by a minimum of two blind peer reviewers. all editorial decisions were made by the independent academic editor. all authors have provided signed confirmation of their compliance with ethical and legal obligations including (but not limited to) use of any copyrighted material, compliance with ICMJE authorship and competing interests disclosure guidelines and, where applicable, compliance with legal and ethical guidelines on human and animal research participants. provenance: the authors were invited to submit this paper.

show abstract

Survival of Patients With Peripheral T-Cell Lymphoma After First Relapse or Progression: Spectrum of Disease and Rare Long-Term Survivors

Abstract: Most patients with relapsed or refractory PTCL have poor outcomes with short survival. Select patients with good PS have more favorable outcomes with standard chemotherapy.

Cited by 348 publications

References 15 publications

Brentuximab vedotin in refractory or relapsed peripheral T-cell lymphomas: the French named patient program experience in 56 patients

Brentuximab vedotin in refractory or relapsed peripheral T-cell lymphomas: the French named patient program experience in 56 patients

Early application of related SCT might improve clinical outcome in adult T-cell leukemia/lymphoma

New Therapies in T-cell Lymphoma

Contact Info

Product

Resources

About